ABL001 is a potent, selective BCR-ABL1 inhibitor that maintains activity across most mutations, including T315I, with a distinct, allosteric mechanism of action. It is currently undergoing phase III clinical studies in chronic myelogenous leukemia patients. Dual allosteric and catalytic BCR-ABL1 inhibition may allow for tumor eradication in patients with CML. The structure guided discovery of ABL001 targeting the myristoyl pocket of the ABL1 kinase by integrating X-ray crystallography, NMR and molecular modeling will be discussed.
